← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Geron Corporation (GERN) 10-Year Financial Performance & Capital Metrics

GERN • • Industrial / General
HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology
AboutGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Show more
  • Revenue $77M +32386.9%
  • EBITDA -$173M +10.6%
  • Net Income -$175M +5.2%
  • EPS (Diluted) -0.27 +15.6%
  • Gross Margin 98.37% -1.6%
  • EBITDA Margin -224.06% +99.7%
  • Operating Margin -225.64% +99.7%
  • Net Margin -226.73% +99.7%
  • ROE -66.09% +41.1%
  • ROIC -44.41% +47.7%
  • Debt/Equity 0.43 +25.3%
  • Interest Coverage -9.39 +59.8%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 178.4%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 13.2% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y52.22%
5Y178.45%
3Y280.92%
TTM522.13%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM60.24%

EPS CAGR

10Y-
5Y-
3Y-
TTM62.26%

ROCE

10Y Avg-44.76%
5Y Avg-66.01%
3Y Avg-78.34%
Latest-43.9%

Peer Comparison

Hematologic Oncology
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
INCYIncyte Corporation20.66B105.24701.6014.76%24.69%25.55%1.21%0.01
TGTXTG Therapeutics, Inc.4.88B30.71204.7340.8%13.31%21.87%1.14
AGIOAgios Pharmaceuticals, Inc.1.62B27.802.3936.07%-8.96%-31.24%0.04
CLRBCellectar Biosciences, Inc.15.48M3.65-0.09-200.99%0.03
CASICASI Pharmaceuticals, Inc.21.37M1.04-0.41-15.77%-183.93%-301.8%11.96
VORVor Biopharma Inc.308.06M14.06-0.41-94.52%0.33
FATEFate Therapeutics, Inc.121.12M1.05-0.64-78.55%-21.87%-66.69%0.27
KPTIKaryopharm Therapeutics Inc.121.95M6.66-0.71-0.55%-87.43%

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+36.37M6.16M1.06M1.07M460K253K1.39M596K237K76.99M
Revenue Growth %30.54%-0.83%-0.83%0%-0.57%-0.45%4.51%-0.57%-0.6%323.87%
Cost of Goods Sold+9.57M14.7M8.44M12.72M51.27M50.05M0001.26M
COGS % of Revenue0.26%2.38%7.92%11.94%111.46%197.83%---0.02%
Gross Profit+26.8M-8.53M-7.37M-11.66M-50.81M-49.8M1.39M596K237K75.74M
Gross Margin %0.74%-1.38%-6.92%-10.94%-110.46%-196.83%1%1%1%0.98%
Gross Profit Growth %4.46%-1.32%0.14%-0.58%-3.36%0.02%1.03%-0.57%-0.6%318.57%
Operating Expenses+35.62M36.81M30.32M32.14M21.69M27.11M115.39M139.15M194.18M249.47M
OpEx % of Revenue0.98%5.97%28.47%30.15%47.16%107.17%82.84%233.47%819.33%3.24%
Selling, General & Admin17.79M18.76M19.29M18.71M21.69M27.11M29.66M43.63M69.14M145.73M
SG&A % of Revenue0.49%3.04%18.11%17.55%47.16%107.17%21.3%73.2%291.71%1.89%
Research & Development17.83M18.05M11.03M13.43M52.07M51.49M85.73M95.52M125.05M103.74M
R&D % of Revenue0.49%2.93%10.36%12.6%113.2%203.51%61.54%160.27%527.62%1.35%
Other Operating Expenses1.31M00-154K-52.07M-51.49M0000
Operating Income+-559K-30.65M-29.25M-31.07M-72.5M-76.91M-114M-138.55M-193.94M-173.73M
Operating Margin %-0.02%-4.97%-27.47%-29.15%-157.62%-304%-81.84%-232.47%-818.33%-2.26%
Operating Income Growth %0.98%-53.82%0.05%-0.06%-1.33%-0.06%-0.48%-0.22%-0.4%0.1%
EBITDA+-503K-30.57M-29.18M-31.01M-72.44M-76.75M-113.22M-137.68M-192.91M-172.51M
EBITDA Margin %-0.01%-4.96%-27.4%-29.09%-157.48%-303.38%-81.27%-231.01%-813.97%-2.24%
EBITDA Growth %0.99%-59.77%0.05%-0.06%-1.34%-0.06%-0.48%-0.22%-0.4%0.11%
D&A (Non-Cash Add-back)56K81K76K59K64K158K783K868K1.03M1.22M
EBIT134K-30.65M-29.25M-27.02M-72.5M-76.91M-112.37M-135.02M-175.81M-156.07M
Net Interest Income+589K1.09M1.42M3.25M4.22M1.07M-3.21M-4.35M9.84M1.1M
Interest Income677K1.18M1.42M3.25M4.22M1.83M527K2.53M18.15M19.61M
Interest Expense88K83K000760K3.74M6.88M8.31M18.5M
Other Income/Expense605K1.11M1.34M4.06M3.96M1.3M-2.11M-3.35M9.82M-840K
Pretax Income+46K-29.54M-27.92M-27.02M-68.55M-75.62M-116.11M-141.9M-184.13M-174.57M
Pretax Margin %0%-4.79%-26.21%-25.34%-149.02%-298.88%-83.35%-238.09%-776.91%-2.27%
Income Tax+0000000000
Effective Tax Rate %1%1%1%1%1%1%1%1%1%1%
Net Income+46K-29.54M-27.92M-27.02M-68.55M-75.62M-116.11M-141.9M-184.13M-174.57M
Net Margin %0%-4.79%-26.21%-25.34%-149.02%-298.88%-83.35%-238.09%-776.91%-2.27%
Net Income Growth %1%-643.11%0.05%0.03%-1.54%-0.1%-0.54%-0.22%-0.3%0.05%
Net Income (Continuing)46K-29.54M-27.92M-27.02M-68.55M-75.62M-116.11M-141.9M-184.13M-174.57M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+0.00-0.19-0.18-0.15-0.33-0.28-0.37-0.37-0.32-0.27
EPS Growth %1%-0.05%0.17%-1.2%0.15%-0.32%0%0.14%0.16%
EPS (Basic)0.00-0.19-0.18-0.15-0.33-0.28-0.37-0.37-0.32-0.27
Diluted Shares Outstanding162.66M159.05M159.22M176.5M190.16M271.46M327.63M380.78M570.65M646.03M
Basic Shares Outstanding158.04M159.05M159.22M176.5M190.16M271.46M327.63M380.78M570.65M646.03M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+115.89M116.11M95.97M166.06M141.61M199.86M187.21M180.25M341.35M490.99M
Cash & Short-Term Investments114.04M115.11M94.95M163.56M139.32M196.28M183.72M172.75M333.7M406.57M
Cash Only21.52M13.08M16.6M10.84M13.64M9.93M34.87M56.84M70.02M79.02M
Short-Term Investments92.52M102.03M78.35M152.71M125.68M186.35M148.85M115.9M263.68M327.55M
Accounts Receivable1.21M475K436K1.17M802K722K1.76M3.14M1.66M38.8M
Days Sales Outstanding12.128.14149.43399.93636.371.04K461.951.93K2.55K183.93
Inventory-1.21M-475K-436K-1.17M0000038.71M
Days Inventory Outstanding---------11.25K
Other Current Assets267K268K268K269K270K363K364K4.36M5.99M6.91M
Total Non-Current Assets+32.87M14.14M14.34M19.23M23.91M70.87M38.83M10.33M52.73M102.79M
Property, Plant & Equipment207K183K102K59K2.9M5.95M5.38M4.94M4.73M4.19M
Fixed Asset Turnover175.71x33.67x10.44x18.07x0.16x0.04x0.26x0.12x0.05x18.37x
Goodwill0000000000
Intangible Assets0000000000
Long-Term Investments32.66M13.95M14.24M18.58M19.65M63.39M28.65M043.3M94.52M
Other Non-Current Assets000585K1.35M1.53M4.8M5.39M4.7M4.08M
Total Assets+148.76M130.25M110.31M185.28M165.52M270.73M226.03M190.57M394.08M593.78M
Asset Turnover0.24x0.05x0.01x0.01x0.00x0.00x0.01x0.00x0.00x0.13x
Asset Growth %-0.14%-0.12%-0.15%0.68%-0.11%0.64%-0.17%-0.16%1.07%0.51%
Total Current Liabilities+6.63M7.87M6.52M7.55M28.16M30.94M45.52M76.69M108.07M88.3M
Accounts Payable160K225K503K982K1.18M6.92M6.69M10.19M6.16M8.6M
Days Payables Outstanding6.15.5921.7628.178.4150.46---2.5K
Short-Term Debt000000020.95M46.89M0
Deferred Revenue (Current)0000000000
Other Current Liabilities002.36M3.6M4.83M8.22M8.1M11.53M13.76M43.18M
Current Ratio17.47x14.76x14.73x21.99x5.03x6.46x4.11x2.35x3.16x5.56x
Quick Ratio17.65x14.82x14.80x22.15x5.03x6.46x4.11x2.35x3.16x5.12x
Cash Conversion Cycle---------8.94K
Total Non-Current Liabilities+00002.2M28.84M54.1M33.88M38.06M225.16M
Long-Term Debt0000024.04M49.83M30.21M35.05M118.48M
Capital Lease Obligations00002.2M4.8M4.27M3.67M3.01M2.27M
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities000000000104.42M
Total Liabilities6.63M7.87M6.52M7.55M30.36M59.78M99.62M110.58M146.13M313.46M
Total Debt+00002.55M29.72M55M55.75M85.9M121.72M
Net Debt-21.52M-13.08M-16.6M-10.84M-11.09M19.79M20.13M-1.09M15.88M42.7M
Debt / Equity----0.02x0.14x0.44x0.70x0.35x0.43x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage-6.35x-369.23x----101.20x-30.48x-20.13x-23.33x-9.39x
Total Equity+142.13M122.38M103.8M177.73M135.16M210.95M126.42M80M247.95M280.32M
Equity Growth %0.09%-0.14%-0.15%0.71%-0.24%0.56%-0.4%-0.37%2.1%0.13%
Book Value per Share0.870.770.651.010.710.780.390.210.430.43
Total Shareholders' Equity142.13M122.38M103.8M177.73M135.16M210.95M126.42M80M247.95M280.32M
Common Stock159K159K160K186K200K310K324K390K545K606K
Retained Earnings-928.39M-957.92M-985.84M-1.01B-1.08B-1.16B-1.27B-1.41B-1.6B-1.77B
Treasury Stock0000000000
Accumulated OCI-213K-53K-207K-183K132K78K-173K-219K185K261K
Minority Interest0000000000

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-24.2M-18.37M-20.56M-21.01M-43.83M-66.65M-95.56M-127.38M-167.74M-218.62M
Operating CF Margin %-0.67%-2.98%-19.3%-19.71%-95.28%-263.45%-68.6%-213.72%-707.78%-2.84%
Operating CF Growth %-3.59%0.24%-0.12%-0.02%-1.09%-0.52%-0.43%-0.33%-0.32%-0.3%
Net Income46K-29.54M-27.92M-27.02M-68.55M-75.62M-116.11M-141.9M-184.13M-174.57M
Depreciation & Amortization56K81K76K59K776K935K783K868K1.03M1.22M
Stock-Based Compensation8.4M8.24M8.14M6.37M6.08M6.89M8.08M8M19.35M31.32M
Deferred Taxes2.24M597K310K-365K-1.33M488K191K000
Other Non-Cash Items364K156K200K191K68K264K984K626K-10.06M-8.18M
Working Capital Changes-35.3M2.09M-1.37M-245K19.13M383K10.52M5.03M6.06M-68.41M
Change in Receivables-243K731K39K-528K366K80K-1.04M-1.38M1.49M-36.89M
Change in Inventory0000-366K-80K1.04M1.38M0-37.97M
Change in Payables-873K65K278K479K199K5.73M-232K3.5M-4.03M2.44M
Cash from Investing+73K8.76M22.97M-77.72M27.4M-105.32M71.95M62.07M-180.32M-106M
Capital Expenditures-90K-57K0-16K-413K-401K-207K-431K-830K-680K
CapEx % of Revenue0%0.01%-0.02%0.9%1.58%0.15%0.72%3.5%0.01%
Acquisitions----------
Investments----------
Other Investing-1K-1K22.97M-77.7M27.81M-339K-1.59M1.23M-179.49M0
Cash from Financing+2.58M1.17M1.11M92.97M19.5M168.35M48.56M87.26M362.02M334.37M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing01.17M51K6.95M204K224K3.28M17.35M118.98M159.08M
Net Change in Cash----------
Free Cash Flow+-24.29M-18.43M-20.56M-21.02M-44.24M-67.05M-95.76M-127.81M-168.57M-219.3M
FCF Margin %-0.67%-2.99%-19.3%-19.72%-96.18%-265.03%-68.75%-214.45%-711.28%-2.85%
FCF Growth %-3.63%0.24%-0.12%-0.02%-1.1%-0.52%-0.43%-0.33%-0.32%-0.3%
FCF per Share-0.15-0.12-0.13-0.12-0.23-0.25-0.29-0.34-0.30-0.34
FCF Conversion (FCF/Net Income)-526.00x0.62x0.74x0.78x0.64x0.88x0.82x0.90x0.91x1.25x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)0.03%-22.33%-24.69%-19.19%-43.82%-43.7%-68.84%-137.49%-112.29%-66.09%
Return on Invested Capital (ROIC)-0.4%-19.99%-22.33%-18.34%-37.38%-32.52%-45.32%-92.18%-84.88%-44.41%
Gross Margin73.68%-138.48%-692.21%-1093.53%-11046.09%-19683.4%100%100%100%98.37%
Net Margin0.13%-479.34%-2621.22%-2534.43%-14901.74%-29888.14%-8335.39%-23808.89%-77690.72%-226.73%
Debt / Equity----0.02x0.14x0.44x0.70x0.35x0.43x
Interest Coverage-6.35x-369.23x----101.20x-30.48x-20.13x-23.33x-9.39x
FCF Conversion-526.00x0.62x0.74x0.78x0.64x0.88x0.82x0.90x0.91x1.25x
Revenue Growth3054.47%-83.06%-82.72%0.09%-56.85%-45%450.59%-57.21%-60.23%32386.92%

Revenue by Segment

2024
Revenues Before Adjustments89.42M
Revenues Before Adjustments Growth-
Product76.5M
Product Growth-
Sales Returns And Allowance-225K
Sales Returns And Allowance Growth-
Government Rebates-926K
Government Rebates Growth-
Chargeback And Distributor Service Fees-11.77M
Chargeback And Distributor Service Fees Growth-
Total Gross To Net Adjustments-12.92M
Total Gross To Net Adjustments Growth-

Frequently Asked Questions

Growth & Financials

Geron Corporation (GERN) reported $183.4M in revenue for fiscal year 2024. This represents a 7423% increase from $2.4M in 2011.

Geron Corporation (GERN) grew revenue by 32386.9% over the past year. This is strong growth.

Geron Corporation (GERN) reported a net loss of $80.0M for fiscal year 2024.

Dividend & Returns

Geron Corporation (GERN) has a return on equity (ROE) of -66.1%. Negative ROE indicates the company is unprofitable.

Geron Corporation (GERN) had negative free cash flow of $132.8M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.